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Summary: A subcutaneous, prepectoral, muscle-sparing approach has been 
recently described for implant-based breast reconstruction. This is a pre-
liminary series of 2-stage breast reconstructions by means of tissue expander 
placed subcutaneously with the support of a titanium-coated polypropylene 
mesh. A pilot series of cases was started in 2012. Inclusion criteria were in-
formed consent, age less than 80 years, normal body mass index (range, 
18.5–24.9), no T4 and metastatic cancers, no comorbidities, and nonsmoking 
patients. Expander losses, infections, seromas, skin/nipple necrosis, wound 
dehiscence, and reinterventions were registered in follow-up visits. Further-
more, patients were followed up in second-stage procedures and for at least 
1 year from implant positioning to collect any surgical complication, reinter-
ventions, cosmetic outcome, and oncological data. Between June 2012 and 
March 2014, 25 cases were enrolled in the study. Expander/implant loss rate 
was 0%. Skin/nipple necrosis rate was 4%. Infections rate was 12% after first-
stage and 4% after second-stage procedure. Seromas rate was 0%. Five (20%) 
fat graft procedures were performed over the expander before second-stage 
reconstruction, and no reinterventions were required after second stage. 
Patients mean score was 99 for cosmetic outcome satisfaction, in a 0–100 
scale. Subcutaneous 2-stage reconstruction with synthetic mesh proved safe 
and feasible. Patients satisfaction is very good after 14 months median follow-
up form definitive implant placement. Although the present study involved 
only a small number of cases, a tissue-expander subcutaneous reconstruction 
seems to have promising results. Whenever pectoralis major muscle can be 
spared, a conservative reconstruction might be an option. (Plast Reconstr Surg 
Glob Open 2015;3:e577; doi: 10.1097/GOX.0000000000000549; Published online 
15 December 2015.)
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In the United States, 2-stage implant-based breast reconstruction (IBBR) accounts for approximate-ly 70% of reconstructions after mastectomy,1 and 
majority of reconstructions are performed by means 
of acellular dermal matrices (ADMs).2 Biological ma-
trixes are the most used worldwide,3 although syn-
thetic meshes are widespread too, as titanium-coated 
polypropylene mesh (TiLOOOP Bra, pfm medical, 
Cologne, Germany) in Europe.4 Such devices, ei-
ther ADMs or meshes, are traditionally adopted as 
a muscle extension, creating a “dual plane” cover-
age of tissue expander (TE)/implant, as described 
by Spear et al.5 In 2014, a different approach with 
subcutaneous implant placement by means of a full 
synthetic mesh or ADMs coverage was described in 
direct-to-implant reconstructions.6–8 Moreover, a re-
cent article shows a significant difference in capsular 
thickness between TEs placed subcutaneously and 
those placed in standard submuscular position.9
Aim of this report is to analyze surgical safety and 
long-term outcomes of subcutaneous TE 2-stage re-
construction using a synthetic mesh.
PATIENTS	AND	METHODS
In 2011, a pilot study was approved by the Hospi-
tal Drugs and Devices Service Committee, according 
with Institutional Ethical Committee rules on non-
randomized clinical studies, for evaluation of perfor-
mances of a titanium-coated polypropylene synthetic 
mesh (TiLOOOP Bra) in IBBR.
Patients scheduled at our institution for conser-
vative mastectomies, either nipple-sparing or skin-
sparing mastectomy, were thoroughly informed of 
different reconstruction options, either autologous 
or prosthetic. If TE approach was chosen, patients 
were informed of the muscle-sparing subcutaneous 
option with synthetic mesh coverage only (totally sub-
cutaneous, prepectoral TE adjustment, and wrapped 
in a mesh bag; Fig. 1). Inclusion criteria were age less 
than 80 years and normal body mass index (range, 
18.5–24.9). Exclusion criteria were previous breast 
surgery, T4 and metastatic cancers, refusal to sign 
the consent, comorbidities (diabetes, renal failure, 
heart failure, cardiovascular diseases, hypertension 
at oral medications, pulmonary diseases, hepatic dis-
eases, and metabolic diseases), smoking, and previ-
ous radiotherapy to chest wall. An informed consent, 
with description of surgical technique and compli-
cations, was signed by every woman. A prospective 
digital database was created to encompass all base-
line characteristics, complications, outpatient visits, 
reinterventions, second-stage reconstructions, final 
cosmetic outcome, and oncological follow-up.
Mesh wrapping around TE was loose, consider-
ing final expansion diameter of TE. Outpatient ex-
pansions were done every week or every 2 weeks for 
the first 2 months, with 40–50mL of sterile solution 
each time. Follow-up visits were performed every 2 
months thereafter, even after TE exchange with im-
plant.
Subjective cosmetic evaluation was conducted us-
ing the postoperative BREAST-Q module (Memorial 
Sloan-Kettering Cancer Center and The University 
of British Columbia © 2006, all rights reserved). Ac-
cording to a study on patient-reported quality of 
life,10 the module was divided into multiple indepen-
dent scales: satisfaction with breasts (16 items), sat-
isfaction with outcome (7 items), psychosocial well 
being (10 items), physical well being (16 items), and 
sexual well being (6 items). For each scale, responses 
were summed and transformed into a score, in a 0–
100 scale. Higher scores indicate greater satisfaction 
or quality of life. Cosmetic evaluation with BREAST-
Q was completed within May 2015 for all patients.
RESULTS
Between June 2012 and March 2014, 25 cases 
were submitted to a subcutaneous TE/first-stage 
IBBR. After 10 month median interval, second-stage 
procedures were performed in all cases. Demo-
graphics, oncological data, complications after first 
stage, reinterventions, further complications after 
second stage, and long-term cosmetic outcome, with 
14-month median follow-up from final reconstruc-
tion, are shown in Table 1.
DISCUSSION
On the basics of the rationale that both ADMs 
and synthetic meshes are safe under the mastectomy 
flaps in the inferolateral pole in a combined submus-
Fig. 1. ex vivo te preparation with titanium-coated polypro-
pylene mesh. Complete te wrapping by means of a titanium-
coated polypropylene synthetic mesh bag. a mesh pocket is 
tailored to embrace te and is left loosely bigger than te itself 
considering the maximum te diameter at final expansion.
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cular “dual plane” coverage, we assume that it could 
be safe to cover breast prostheses entirely with such 
devices. Results in subcutaneous direct-to-implant 
reconstructions are published in three 2014 studies, 
with either titanium-coated mesh or ADMs.6–8 Same 
approach can be used in 2-stage TE reconstruction 
as well, particularly because of lesser tension on skin 
flaps, whenever a 2-stage procedure is chosen either 
for oncological or for surgical reasons. Subcutane-
ous reconstructions recreate the anatomical position 
and ptosis of breast gland. Besides, pectoralis muscle 
can be spared, avoiding drawbacks such as prosthesis 
“animation” (See video, Supplemental Digital Con-
tent 1, which displays a subcutaneous TE. Monolat-
eral subcutaneous TE (full height, full projection) 
3 months after intervention during chemotherapy. 
This video is available in the “Related Videos” sec-
tion of the full-text article on http://links.lww.com/
PRSGO/A159).
In present series, no TE failure (TE removal), 1 
(4%) skin/nipple necrosis, 3 (12%) skin/wound in-
fections, and 1 (4%) hematoma are reported. Com-
plications were all treated conservatively. Five (20%) 
reinterventions in between first and second stage 
were all fat graft procedures over the TE, performed 
in cases submitted to postoperative radiation (always 
performed before second-stage reconstruction) to 
ameliorate the subcutaneous softness and thickness.
Only 1 (4%) complication, infection, occurred 
after second-stage procedures. Final cosmetic out-
come, after 14-month median follow-up, was judged 
with a mean score of 99 in a 0–100 scale by patient-
reported evaluations.
Intraoperatively, mesh appears thin, flexible, and 
completely integrated within TE capsule (Figs. 2,3). 
The use of ADMs or synthetic meshes provides a 
scaffold between TE and skin flaps. Such devices are 
Table 1. Demographics, Oncological Data, Surgical 
Complications and Long-Term Cosmetic Outcome 
of Subcutaneous Implant-Based 2-Stage Breast 
Reconstruction
Demographics	and	oncological	data	of	included	patients
  No. of cases 25
  Age: median (range) 60 (40–77)
  BMI: median (range) 22 (19–24)
  Intervention: no. of cases (%)
   Monolateral 25 (100)
   Skin-sparing mastectomy 13 (52)
   Nipple-sparing mastectomy 12 (48)
  Pathology: no. of cases (%)
   pT0 0 (0)
   pTis-pT1 14 (56)
   pT2 8 (32)
   pT3 3 (12)
   pN 0 10 (40)
   pN 1 9 (36)
   pN 2 5 (20)
   pN 3 1 (4)
  Neo-adjuvant chemotherapy:  
  no. of cases (%)
8 (32)
  Adjuvant chemotherapy:  
  no. of cases (%)
12 (48)
  Adjuvant radiation therapy:  
  no. of cases (%)
7 (28)
First-stage, subcutaneous  
TE placement
  Overall complications:  
no. of cases (%)
5 (20)
   TE loss 0 (0)
   Skin-nipple necrosis* 1 (4)
   Seroma 0 (0)
   Wound dehiscence 0 (0)
   Wound-skin infection* 3 (12)
   Hematoma* 1 (4)
   Atopic reaction versus  
   mesh or prosthesis
0 (0)
  Reinterventions† 5 (20)
Second-stage, TE exchange for definitive implant
  No. of cases (%) 25
  Interval from first-stage: months,  
  median (range)
10 (6–14)
  Overall complications: no. of  
  cases (%)
1 (4)
   Implant loss 0 (0)
   Skin-nipple necrosis 0 (0)
   Seroma 0 (0)
   Wound dehiscence 0 (0)
   Wound-Skin infection* 1 (4)
   Hematoma 0 (0)
   Atopic reaction versus prosthesis 0 (0)
  Reinterventions 0 (0)
Long-term follow-up after second stage
  Last follow-up in May 2015:  
  months, median (range)
14 (7–23)
  Mortality: no. of cases (%) 0 (0)
  Local recurrence (chest wall/
axilla): no. of cases (%)
1 (4)
  Distant metastases 2 (8)
Subjective cosmetic evaluation, BREAST-Q  
scores‡
  No. of evaluated patients 25
   Satisfaction with breasts  
   mean (SD); median (range)
58 (23); 64 (16–95)
   Satisfaction with outcome  
   mean (SD); median (range)
99 (9); 100 (63–100)
   Psychosocial well being mean  
   (SD); median (range)
77 (26); 87 (18–100)
   Physical well being mean (SD);  
   median (range)
94 (12); 96 (54–100)
   Sexual well being mean (SD);  
   median (range)
56 (31); 53 (4–100)
*Treated conservatively without implant removal. Wound-skin infection 
was defined as any swelling and redness of surgical site, which required 
an antibiotic treatment either per os or intravenously. Infection rate 
was considered in the follow-up period until TE exchange with implant 
after first stage and until 1 year after second-stage procedure, according 
to Centers for Disease Control and Prevention guidelines.11
†Reinterventions were because of margin infiltration in 1 case and to 
fat graft over the expander in 4 cases.
‡For each scale, item responses were summed and transformed into a 
score, ranging from 0 to 100. Higher scores indicate greater satisfac-
tion or quality of life.
BMI, body mass index.
Table 1. (Continued )
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effective to fix TEs or implants in the proper posi-
tion, giving support and preventing displacements. 
Direct-to-implant studies6–8 show a seemingly equal 
safety with either technique. Our results both in a 
previous study6 and in this series show a 0% seroma 
rate, probably because of the loose knitwork of mesh 
that allows an easy fluid drainage without closed 
spaces. Seroma still remains the most frequent 
complication with ADMs.2 A possible drawback of a 
subcutaneous TE placement is the thin medial as-
pect of reconstructed breast, which can cause rip-
pling and make visible the TE or implant later on. 
This limit can be addressed, whenever significant, 
with a fat graft procedure.
Obvious limits of this report are small number 
of cases and absence of a randomized control 
group.
In conclusion, these results might open a way 
toward the subcutaneous TE reconstruction as 
an alternative. As conservative mastectomies have 
changed the breast surgical oncology scenario, it is 
time to consider also a “conservative reconstruction” 
approach sparing muscles.
CONCLUSIONS
After the introduction of subcutaneous direct-to-
implant breast reconstructions by means of soft tis-
sue replacement devices, such as ADMs and synthetic 
meshes, a preliminary experience of subcutaneous TEs 
placement is reported in this series. Twenty-five patients 
were submitted to subcutaneous 2-stage reconstruction 
with TE completely wrapped in a titanium-coated poly-
propylene mesh and followed up even after second-
stage procedure with a 14-month median long-term 
evaluation using BREAST-Q self reported module.
No TE/implant failures with removal were reg-
istered, and complications were minor and treated 
conservatively. Long-term subjective cosmetic results 
are excellent. This pilot experience with subcutane-
ous TE 2-stage reconstruction shows that, granted 
some selection criteria, this type of “anatomical” re-
construction is feasible, avoiding the drawbacks of 
muscle “animation” over the implant.
Fig. 2. titanium-coated synthetic mesh integration within 
capsule. appearance of capsule during a second-stage pro-
cedure, after te removal of a reconstructed breast by means 
of a titanium-coated polypropylene mesh.
Fig. 3. Microscopic appearance of titanium-coated synthetic 
mesh integration within capsule. Histology shows cystic 
spaces containing pale material consistent with the titani-
um-coated polypropylene mesh. Mild chronic inflamma-
tory response with histiocytes and foreign body giant cells 
surround the mesh. all elements are completely integrated 
within fibroblastic tissue.
Video 1. see video, supplemental Digital Content 1, which 
displays a subcutaneous te. Monolateral subcutaneous te 
(full height, full projection) 3 months after intervention dur-
ing chemotherapy. this video is available in the “Related Vid-
eos” section of the full-text article on http://links.lww.com/
pRsGo/a159.
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